There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC]. especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR]. or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fluoropyrimidine approved for monotherapy in mBC. https://www.sylvaingoudreau.com/product-category/pickles/